Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week

Core Insights - Achieve Life Sciences, Inc. is focused on developing and commercializing cytisinicline for nicotine dependence, with significant milestones expected in 2025 [1][5]. Company Overview - Achieve Life Sciences is a late-stage pharmaceutical company dedicated to addressing nicotine addiction through cytisinicline [5]. - The company has completed two Phase 3 clinical trials involving over 1,600 subjects for smoking cessation and one Phase 2 trial for vaping cessation [3][5]. Clinical Development - Achieve plans to submit a New Drug Application (NDA) for cytisinicline as a smoking cessation aid in Q2 2025 [3][5]. - A single Phase 3 clinical trial for vaping cessation is expected to commence in Q3 2025 [3][5]. Market Context - Approximately 29 million adults smoke combustible cigarettes, with tobacco use being the leading cause of preventable death globally, accounting for over 8 million deaths annually [6]. - There are over 11 million adults in the U.S. who use e-cigarettes, with no FDA-approved treatments specifically for nicotine e-cigarette cessation [7]. Product Mechanism - Cytisinicline is a plant-based alkaloid that interacts with nicotinic acetylcholine receptors in the brain, aiming to reduce nicotine cravings and the satisfaction derived from nicotine products [8].